When telephone lines go down, or Internet connections are lost, our communities temporarily come to a halt. What if something similar were found to be happening in Parkinson's? This is the focus of Dr. Schmitz and her team at the PDF Research Center at Columbia University Medical Center.
PDF Grant Programs
Are you interested in furthering Parkinson's science? View PDF's open grant programs.
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.
PDF's targeted PubMed search provides you with access to journal articles from the last 90 days that may be pertinent to Parkinson's disease research.
Not what you're looking for? Do you need informational publications about Parkinson's targeted for people living with Parkinson's, caregivers and family members? Please browse PDF's educational materials and programs - which are all available electronically or in print. Order for yourself, a loved one or in bulk for your patients or support group.
J Neurol Neurosurg Psychiatry 2013 Nov; 84(11):e2
Authors: Peter Connick, Siddharthan Chandran
University of Edinburgh.
Multiple Sclerosis affects over 2.1 million people worldwide,(1) with over half of the prevalent population characterised by progressive forms of disease that result in the steady accumulation of fixed disability.(2) The absence of treatments for progressive MS therefore represents a major unmet clinical need.(3) Based on increasing experimental evidence that mesenchymal stem cells (MSCs) have biological properties of potential therapeutic relevance,(4) and beneficial effects across a range of disease models,(5) we assessed the safety and efficacy of autologous MSCs as a potential neuroprotective therapy for secondary progressive MS.(6) METHODS: Ten patients with secondary progressive MS involving the visual pathways (EDSS 5.5 to 6.5), received intravenous infusion of autologous bone marrow-derived MSCs derived using the European Group for Blood and Marrow Transplantation ex-vivo expansion procedures in a prospective open label phase IIA proof of concept study, registered at ClinicalTrials.gov NCT00395200. Adverse events were compared between pre-treatment and post-treatment periods of up to 20 and 10 months respectively. Using the anterior visual pathway as a model of wider disease, efficacy outcomes were also chosen to assess change at the point of treatment in functional, structural, and physiological measures. Blinded endpoint analyses were used for electrophysiological and selected imaging outcomes.
PMID: 24109005 [PubMed - as supplied by publisher]